Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reflects strong financial performance, with significant revenue growth across products and increased guidance for 2025. The Q&A session highlighted effective strategies for growth, such as pharmacy intervention programs and increased VGCC testing, which support optimistic future prospects. While management avoided specifics on business development deals, the overall sentiment is positive with robust financial health and strategic initiatives in place. Given the market cap of $1.78 billion, the stock is likely to react positively to these developments, with a predicted stock price increase of 2% to 8%.
Key Financial Performance
Total Revenues (2025) $589 million, a 19.8% increase year-over-year. This growth was attributed to strong market opportunities and operational excellence.
Net Product Revenue (2025) $588.8 million, a 20.3% increase year-over-year. The increase was driven by patient identification and market penetration.
FIRDAPSE Revenue (2025) $358.4 million, a 17% increase year-over-year. Growth was due to expanded patient identification and market penetration in idiopathic and cancer-associated LEMS.
AGAMREE Revenue (2025) $117.1 million, a 154.3% increase year-over-year. Growth was driven by successful launch strategies and penetration into centers of excellence.
FYCOMPA Revenue (2025) $113.3 million, despite loss of exclusivity in May 2025. Outperformed expectations due to strong market presence before generic competition.
Net Income Before Taxes (2025) $283.5 million, a 31.1% increase year-over-year. Growth was attributed to strong revenue performance and financial discipline.
GAAP Net Income (2025) $214.3 million, a 30.8% increase year-over-year. This reflects strong operational performance.
Non-GAAP Net Income (2025) $346.2 million, reflecting adjustments for amortization, stock-based compensation, and other factors.
Cash and Cash Equivalents (End of 2025) $709.2 million, an increase of $191.6 million from 2024. Growth was driven by cash generated from operating activities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FIRDAPSE: Revenue for 2025 was $358.4 million, a 17% increase year-over-year. It remains the only FDA-approved therapy for Lambert-Eaton myasthenic syndrome (LEMS). Growth driven by patient identification and market penetration. Addressable market opportunity exceeds $1 billion. Focus on expanding patient identification for idiopathic LEMS and promoting updated NCCN guidelines for cancer-associated LEMS. Increased VGCC testing and oncology network engagement to expand addressable market.
AGAMREE: Revenue for 2025 was $117.1 million, a 154.3% increase year-over-year. Approved for Duchenne Muscular Dystrophy (DMD). Growth driven by targeting centers of excellence and ongoing SUMMIT study. Addressable market opportunity exceeds $1 billion. Targeting earlier disease detection and deeper market penetration. SUMMIT study aims to differentiate AGAMREE further and explore potential indications beyond DMD.
FYCOMPA: Revenue for 2025 was $113.3 million despite loss of exclusivity. Forecasted 2026 revenue is $40-$45 million due to generic competition.
Revenue Growth: 2025 total revenues grew 19.8% year-over-year to $589 million, exceeding guidance. Net income before taxes increased by 31.1% to $283.5 million.
Operational Efficiency: Improved patient identification and conversion efficiency for FIRDAPSE. Enhanced provider familiarity and reduced discontinuations for AGAMREE.
Business Development: Conducted over 100 assessments in 2025, with 90% inbound. Focused on rare disease products with peak sales up to $500 million. Expanded search to include late-stage development therapies.
Portfolio Optimization: Discontinued promotion of FYCOMPA due to generic competition. Focused on maximizing value of FIRDAPSE and AGAMREE through targeted initiatives.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Generic competition for FYCOMPA: The entry of generic competition in 2025 has led to a significant decline in FYCOMPA's revenue, with further erosion expected in 2026. This poses a challenge to maintaining revenue levels from this product.
Patent litigation for FIRDAPSE: A lawsuit against Hetero USA is ongoing, with a trial set for March 2026. This legal uncertainty could impact the company's ability to protect its intellectual property and revenue from FIRDAPSE.
IRA impact on Medicare Part D revenue: The Inflation Reduction Act (IRA) is expected to increase gross-to-net adjustments for Medicare Part D, impacting FIRDAPSE's net product revenue in 2026 and beyond.
Royalty obligations for AGAMREE: The company faces increasing royalty obligations as AGAMREE's net sales grow, including a $12.5 million milestone payment triggered in 2025. These obligations could pressure profit margins.
Dependence on rare disease market: The company's focus on rare disease products, while a strength, also makes it vulnerable to market-specific risks such as limited patient populations and high competition for niche therapies.
Supply chain and operational risks: Although not explicitly mentioned, the company's reliance on specialized products and markets implies potential risks related to supply chain disruptions or operational inefficiencies.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Revenue Guidance: Total revenue is projected to be between $615 million and $645 million, indicating confidence in continued growth.
FIRDAPSE Revenue Forecast: 2026 revenue is expected to be between $435 million and $450 million, reflecting a 21.4% to 25.6% increase. Focus will be on expanding patient identification and promoting updated NCCN guidelines for cancer-associated LEMS.
AGAMREE Revenue Forecast: 2026 revenue is projected to be between $140 million and $150 million, representing a 19.6% to 28.1% growth. Efforts will include earlier disease detection, deeper market penetration, and advancing the SUMMIT study.
FYCOMPA Revenue Forecast: 2026 revenue is expected to be between $40 million and $45 million, despite generic competition. The product will no longer be actively promoted.
Business Development Strategy: The company plans to pursue opportunities for rare disease products with peak sales potential of up to $500 million, focusing on late-stage development therapies with positive proof of concept and differentiated profiles.
Research and Development Expenses: 2026 R&D costs are forecasted to be between $17.5 million and $22.5 million, primarily supporting ongoing AGAMREE studies.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Plan: During the fourth quarter of 2025, the company repurchased $25.3 million of common stock under its share repurchase plan. The company stated that its life cycle management and business development activities will not be adversely affected by these share repurchases. The company believes its current funds and expected continued generation of cash from operations provide financial flexibility to fund existing R&D programs, meet potential contractual obligations, and support strategic initiatives, business development, and portfolio expansion efforts.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the drivers underpinning the growth implied within the 2026 guidance for FIRDAPSE and AGAMREE?
A:For FIRDAPSE, growth is driven by opportunities in idiopathic LEMS (30% penetrated) and cancer-associated LEMS (under 10% penetrated). Identified patient pool increased from 500 to over 600. Pharmacy intervention programs reduced discontinuations by 12%. VGCC testing increased by 21% year-over-year. For AGAMREE, growth is driven by broad adoption across top COEs, 20% growth expected in 2026, and decreased discontinuations and cancellations.
Q:What is the biggest driver of the increase in FIRDAPSE guidance for 2026 and beyond?
A:The biggest drivers are the greater than 600 pool of patients in their diagnostic journey, 21% year-on-year growth in VGCC testing, and improved efficiency in getting patients on treatment. Incremental patients from cancer-associated LEMS are expected in the second half of the year.
Q:What is the impact of the pharmacy intervention program on FIRDAPSE?
A:The pharmacy intervention program, initiated in June of last year, led to a 12% decrease in discontinuations of patients who reached their optimal therapeutic dose.
Q:What are the key factors considered in business development (BD) activities?
A:Key factors include a differentiated product profile, alignment on vision with partners, near-term accretive opportunities, and a clear regulatory path. The company remains diligent and thoughtful in its approach.
Q:What is the significance of the median age of new AGAMREE enrollees dropping by a year?
A:The median age dropping to closer to 11 years (from 12) indicates younger patients are being enrolled. Younger patients have greater adherence to therapy and are more likely to experience long-term benefits. About 10% of patients are starting AGAMREE as their first steroid.
Q:What is the current reimbursement rate for AGAMREE and challenges faced?
A:The reimbursement rate is tracking above 85%, closer to 90%. Challenges include step edit requirements, but bridge treatment is provided until approval is obtained.
Q:How does the SUMMIT open-label expansion affect AGAMREE's forecast and additional indications?
A:The SUMMIT trial aims to evaluate long-term benefits and glucocorticoid side effects. Current data from Santhera is encouraging but not yet in the label, so no significant impact is built into the forecast. Additional indications are being evaluated.
Q:What is the expected growth trajectory for FIRDAPSE in 2026?
A:Growth is expected to be strong in the first half due to idiopathic LEMS enrollments, with incremental patients from cancer-associated LEMS in the second half. VGCC testing is a key indicator of conversion to therapy.
Q:How does the Phase 1a readout for AGAMREE impact future plans?
A:The Phase 1a readout, expected in the first half of 2026, will evaluate biomarkers of inflammation and immunosuppressive effects. Results will guide life cycle management opportunities and potential additional indications.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer to whether a business development deal will occur this year, citing a diligent and thoughtful approach without committing to a timeline.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AGAMRE Ruzurgi
AGAMREE steroid
DMD AGAMREE
DMD center
DMD patient
Executive VP
FIRDAPSE AGAMREE
FIRDAPSE evidence
FIRDAPSE treatment
FYCOMPA AGAMRE
IRA
Japan
LEMS cancer
Ruzurgi stock
SGA
Treasurer CFO
VP Treasurer
assistance program
awareness
capability
class
competition
contribution
development activity
disease community
disease product
disorder
evidence FDA
excess
identification
increase FIRDAPSE
infrastructure
journey
market product
program FYCOMPA
reduction
revenue FIRDAPSE
revenue end
sale increase
share repurchase
treatment patient
CPRX Transcript
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary reflects strong financial performance, with significant revenue growth across products and increased guidance for 2025. The Q&A session highlighted effective strategies for growth, such as pharmacy intervention programs and increased VGCC testing, which support optimistic future prospects. While management avoided specifics on business development deals, the overall sentiment is positive with robust financial health and strategic initiatives in place. Given the market cap of $1.78 billion, the stock is likely to react positively to these developments, with a predicted stock price increase of 2% to 8%.
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
Neutral12-8
CPRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
